Beta-Crosslaps (CTX) (Serum, frozen (s))
| Specimens: | 1 ml Serum, frozen (s) |
| Preanalytics/Notes: | Fasting blood sampling in the morning between 7.30 and 8.30am. There is a substantial circadian rhythm, therefore the time of sampling of further control examinations is important. Strict fasting blood sampling is important, the patient is only allowed to drink water (no coffee or tea, no drinks containing sugar) before blood sampling! For long-term analysis, the samples must always be collected under the same conditions as the first sample. After blood sampling, let coagulate for approx. 30 - 45 min., centrifuge, remove serum with a pipette and transfer into a new tube, freeze and dispatch deep-frozen. At room temperature, the parameter is stable for 8 h in the serum. Patients receiving high doses of biotin (> 5 mg / day) should be sampled at least 8 hours after the last application, as high levels of biotin may interfere with the test system. |
| Method: | ECLIA |
| Dimension: | ng/ml |
| Set-up: | Mon Tue Wed Thu Fri Sat Sun |
| Duration: | 1 day |
| Indication/Significance: |
|
| Interpretation: |
Increased: Elevated more… Increased: Elevated values are indicative of an increased destruction of bone. CTX (Beta-CrossLaps) is considered the most reliable marker for increased destruction of bone (osteoporosis), in particular in postmenopausal women. For a correct assessment, it is urgently required that fasting blood sampling takes place in the morning by 8.30am at the latest because of the substantial circadian rhythm. There are only slight diurnal variations in dialysis patients. Elevated levels of Beta-CrossLaps are indicative of an increased destruction of bone. A check of the vitamin D supply (determination of 25(OH) vitamin D) is recommended in the case of elevated levels. Hyperthyrosis, hyperparathyroidism or glycocorticoid therapy may also cause increased destruction of bone. To monitor an antiresorptive therapy, the Beta-CrossLaps analysis should be combined with the analysis of a bone formation marker (ostasis/bone AP). |
| Further tests: | Markers of bone formation, e.g. ostasis/bone AP |
Reference range / valuation (openclose)
| both sex | ||
|---|---|---|
|
Reference range: Female: < 0.57 ng/ml Male: up to 50 years: < 0.58 ng/ml 50 - 70 years: < 0.70 ng/ml 70 - 99 years: < 0.85 ng/ml Dialysis patients (with normal bone degradation): 0.5 - 2.1 ng/ml The reference ranges are valid only for fasting blood sampling (after 12 hours of fasting) taken between 07:30 - 08:30 a.m. (diurnal rhythm). Only minor fluctuations are observed in dialysis patients. High levels of beta-cross laps indicate increased bone degradation. In such cases, we suggest the analysis of Vitamin D (25-hydroxy-cholecalciferol). Possible causes of increased bone degradation include hyperthyroidism, hyperparathyroidism and glucocorticoid therapy. To monitor anti-resorption therapy, we suggest the analysis of ostase (bonespecific alkaline phosphatase) together with beta-cross laps. |
||
initial letter
Abrechnung GOÄ
Die Kosten werden für den i. d. R. genutzten 1,15-fachen GOÄ-Satz dargestellt. Wird die Untersuchung nicht in Ihrem regionalen Labor durchgeführt, erfolgt die Analyse in dem Labor, das im Leistungsverzeichnis genannt ist. In diesem Fall gilt der dort für die Untersuchung angegebene Preis.